Literature DB >> 29219788

Differential patterns of metastatic dissemination across medulloblastoma subgroups.

Michal Zapotocky1,2, Daddy Mata-Mbemba3, David Sumerauer2, Petr Liby4, Alvaro Lassaletta1, Josef Zamecnik5, Lenka Krskova5, Martin Kyncl6, Jan Stary2, Suzanne Laughlin3, Anthony Arnoldo7, Cynthia Hawkins7, Uri Tabori1, Michael D Taylor8, Eric Bouffet1, Charles Raybaud3, Vijay Ramaswamy1,9.   

Abstract

OBJECTIVE Metastatic dissemination is a major treatment challenge and cause of death in patients with medulloblastoma. However, the influence of molecular biology on the pattern of metastatic dissemination at diagnosis is not known. In this study, the authors sought to define the location, pattern, and imaging characteristics of medulloblastoma metastases across subgroups at diagnosis. METHODS A consecutive cohort of patients with metastatic medulloblastoma at The Hospital for Sick Children and the University Hospital Motol, who underwent up-front MRI of the craniospinal axis, was assembled and allocated to subgroups using NanoString limited gene-expression profiling. Radiological characteristics (including location, morphology, size, diffusion restriction, and contrast enhancement) were discerned through a retrospective review. RESULTS Forty metastatic medulloblastomas were identified with up-front neuroimaging of the craniospinal axis: 5 sonic hedgehog (SHH), 16 Group 3, and 19 Group 4 metastases. Significant subgroup-specific differences were observed, particularly with respect to tumor location, size, and morphology. Group 3 metastases were most frequently laminar compared with a more nodular pattern in Group 4 (14 of 16 in Group 3 vs 8 of 19 in Group 4; p = 0.0004). Laminar metastases were not observed in patients with SHH medulloblastoma. Suprasellar metastases are highly specific to Group 4 (p = 0.016). Two of the 5 SHH cases had multifocal lesions in the cerebellum, raising the possibility that these were in fact synchronous primary tumors and not true metastases. A minority of patients with Group 4 metastases harbored metastatic deposits that did not enhance on MRI after contrast administration, often in patients whose primary tumor did not enhance. CONCLUSIONS The location, morphology, and imaging characteristics of metastatic medulloblastoma differ across molecular subgroups, with implications for diagnosis and management. This suggests that the biology of leptomeningeal dissemination differs among medulloblastoma subgroups.

Entities:  

Keywords:  MRI; SHH = sonic hedgehog; WNT = wingless; medulloblastoma; metastasis; molecular subgroups; oncology

Mesh:

Year:  2017        PMID: 29219788     DOI: 10.3171/2017.8.PEDS17264

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  14 in total

1.  Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort.

Authors:  A Stock; M Mynarek; T Pietsch; S M Pfister; S C Clifford; T Goschzik; D Sturm; E C Schwalbe; D Hicks; S Rutkowski; B Bison; M Pham; M Warmuth-Metz
Journal:  AJNR Am J Neuroradiol       Date:  2019-10-24       Impact factor: 3.825

2.  An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.

Authors:  Sangeet Lal; Diego Carrera; Joanna J Phillips; William A Weiss; Corey Raffel
Journal:  Neuro Oncol       Date:  2018-11-12       Impact factor: 12.300

Review 3.  Magnetic Resonance Imaging in the Contemporary Management of Medulloblastoma: Current and Emerging Applications.

Authors:  Archya Dasgupta; Madan Maitre; Sona Pungavkar; Tejpal Gupta
Journal:  Methods Mol Biol       Date:  2022

4.  Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.

Authors:  John T Lucas; Christopher L Tinkle; Jie Huang; Arzu Onar-Thomas; Sudharsan Srinivasan; Parker Tumlin; Jared B Becksfort; Paul Klimo; Frederick A Boop; Giles W Robinson; Brent A Orr; Julie H Harreld; Matthew J Krasin; Paul A Northcott; David W Ellison; Amar Gajjar; Thomas E Merchant
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

5.  Molecular subgrouping of medulloblastoma based on few-shot learning of multitasking using conventional MR images: a retrospective multicenter study.

Authors:  Xi Chen; Zhen Fan; Kay Ka-Wai Li; Guoqing Wu; Zhong Yang; Xin Gao; Yingchao Liu; Haibo Wu; Hong Chen; Qisheng Tang; Liang Chen; Yuanyuan Wang; Ying Mao; Ho-Keung Ng; Zhifeng Shi; Jinhua Yu; Liangfu Zhou
Journal:  Neurooncol Adv       Date:  2020-06-22

6.  Molecular correlates of cerebellar mutism syndrome in medulloblastoma.

Authors:  Rashad Jabarkheel; Nisreen Amayiri; Derek Yecies; Yuhao Huang; Sebastian Toescu; Liana Nobre; Donald J Mabbott; Sniya V Sudhakar; Prateek Malik; Suzanne Laughlin; Maisa Swaidan; Maysa Al Hussaini; Awni Musharbash; Geeta Chacko; Leni G Mathew; Paul G Fisher; Darren Hargrave; Ute Bartels; Uri Tabori; Stefan M Pfister; Kristian Aquilina; Michael D Taylor; Gerald A Grant; Eric Bouffet; Kshitij Mankad; Kristen W Yeom; Vijay Ramaswamy
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

7.  Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.

Authors:  Jia Wei; Ling Ma; Chenglong Li; Christopher R Pierson; Jonathan L Finlay; Jiayuh Lin
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

Review 8.  ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer.

Authors:  Laura Escudero; Francisco Martínez-Ricarte; Joan Seoane
Journal:  Cancers (Basel)       Date:  2021-04-21       Impact factor: 6.639

Review 9.  Medulloblastomics revisited: biological and clinical insights from thousands of patients.

Authors:  Volker Hovestadt; Olivier Ayrault; Fredrik J Swartling; Giles W Robinson; Stefan M Pfister; Paul A Northcott
Journal:  Nat Rev Cancer       Date:  2019-12-09       Impact factor: 69.800

Review 10.  Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.

Authors:  Otília Menyhárt; Felice Giangaspero; Balázs Győrffy
Journal:  J Hematol Oncol       Date:  2019-03-15       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.